Skip to content
Menu

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11.25

Benzinga Newsdesk 22 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.

Read at benzinga.com